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Abstract
Development of HCV infection is typically followed by chronic hepatitis C (CHC) in most patients, while spontaneous HCV
viral clearance (SVC) occurs in only a minority of subjects. Compared with the widespread application of HCV RNA testing by
quantitative RT-PCR technique, HCV core antigen detection may be an alternative indicator in the diagnosis of hepatitis C
virus infections and in monitoring the status of infectious individuals. However, the correlation and differences between
these two indicators in HCV infection need more investigation, especially in patients coinfected by HIV-1. In this study, a
total of 354 anti-HCV and/or anti-HIV serum positive residents from a village of central China were enrolled. Besides HCV-
related hepatopathic variables including clinical status, ALT, AST, anti-HCV Abs, as well as the altered CD4+/CD8+ T cell
counts, HCV core antigen and HCV viral load were also measured. The concentration of serum HCV core antigen was highly
correlated with level of HCV RNA in CHC patients with or without HIV-1 coinfection. Of note, HCV core antigen
concentration was negatively correlated with CD4+ T cell count, while no correlation was found between HCV RNA level and
CD4+ T cell count. Our findings suggested that quantitative detection of plasma HCV core antigen may be an alternative
indicator of HCV RNA qPCR assay when evaluating the association between HCV replication and host immune status in
HCV/HIV-1 coinfected patients.
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Introduction
Infection of hepatitis C virus (HCV) and human immunodefi-
ciency virus-1 (HIV-1) was prevalent in several provinces of China
owing to unsanitary commercial blood collection practices until
the end of the 1990’s [1–3] while HCV is more frequently
transmitted through unsanitary blood or blood products, com-
pared to HIV-1infection [4–7]. Unlike HIV-1, it was reported that
approximately 14% to 40% of people infected with HCV
spontaneously cleared the virus and had no detectable serum
HCV RNA [8–14]. Anti-HCV seropositive individuals with
detectable HCV RNA were considered to have active HCV
infection and were classified as chronic hepatitis C infection
(CHC), while HCV seropositive individuals with HCV RNA
negative (i.e., viremia-negative) were considered to have a prior
HCV infection and were classified as spontaneous HCV viral
clearance (SVC) [15].
With the development of techniques for direct detection of the
HCV virus (RNA or core protein), it is expected that HCV
infectious status can be evaluated better if the results of HCV
antibodies and virus detection were considered together. Of note,
compared with the widespread application of HCV RNA
detection by using the RT-qPCR technique, the HCV core
antigen assay may be a useful aid in the diagnosis of suspected
hepatitis C viral infections and to monitor the status of infectious
individuals. However, the application and significance of HCV
core antigen assay and its correlation with HCV RNA detection
are still not well investigated, especially on the background of
HIV-1 coinfection.
In this cross-sectional study, we analyzed and compared the
serological and virological characteristics of HCV viremia-positive
and viremia-negative patients in a total of 354 HCV and/or HIV-
1 seropositive subjects. Clinical correlations and the effect of HIV-
associated factors on abnormalities of liver function in HCV/HIV-
1 coinfected patients were also evaluated. The results demonstrat-
ed that serum HCV core antigen testing has comparable sensitivity
and highly stability to HCV RNA qPCR in CHC patients with or
without HIV-1 coinfection and quantitative detection of plasma
HCV core antigen may be a practical alternative to the HCV
RNA qPCR assay in clinical evaluation of HCV infection.
However, HCV core antigen level was negatively correlated with
CD4+ T cell counts and anti-HCV antibody response (S/CO
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23550ratio) was positively correlated with CD4+ T cell counts in HIV
seropositive CHC patients with CD4+ T cell counts less than
1000/ml, while no correlation was found between HCV RNA level
and CD4+ T cell count. Our findings suggested that HCV core
antigen probably may be more sensitive to immune pressure than
HCV RNA under the immunodeficiency condition induced by
HIV-1 coinfection.
Materials and Methods
Establishment of a study cohort
A totalof 1252 residents (account for80% ofthelocal population)
from a village of Shangcai county, Henan province in central China
were investigated for serum HBsAg, anti-HCV antibodies and anti-
HIV antibodies existence by local CDC (Shangcai Center for
Disease Control and Prevention) and local hospital (Shangcai
County People’s Hospital). 354 individuals who were anti-HCV
seropositive and/or anti-HIV-1 seropositive, but negative for
HBsAg, were enrolled in this cross-sectional study in August 2009.
None of the participants received any form of HCV antiviral
therapy. More than 90% of the participants were so-called former
blood donors (FBDs) who have a history of non-standard paid blood
donation and others were their parents, spouse or children. All
participants were interviewed by trained and qualified staff using a
standardized questionnaire, including detailed general information,
blood donation history, and usage of antiviral or antiretroviral
drugs. Anti-HCV antibodies, HCV RNA level, HCV core antigen
level and signs of hepatopathy (clinical status, CD4/CD8 T cell
counts, ALT, AST, GGT, alkaline phosphatase, albumin, bilirubin,
platelet count and liver ultrasound examination) were measured in
all studied subjects. All HIV-1 infected individuals received
regularly (,75%) or intermittently (,10%) first-line highly active
antiretroviral therapy (HAART) regimes consisting of two nucleo-
side reverse transcriptase inhibitors (NRTIs) AZT/ddI (,60%) or
d4T/3TC (,40%), and one non-nucleoside reverse transcriptase
inhibitor (NNRTI) NVP, which were supported by the China
CARES (Community AIDS Resource and Education Services)
program. The study was approved by institutional review
authorities of Peking University Health Science Center and
informed consent forms were signed by all participants. The
characteristics of all subjects at enrollment are presented in Table
S1. An additional nineteen healthy controls were recruited (HIV
andHCVseronegativeandHBsAgnegativesubjects)fromthesame
village (although not included in this study cohort).
Sample collection and clinical evaluation
Serum and plasma were collected at enrollment. Liver
associated enzymes including ALT (alanine aminotransferase),
AST (aspartate aminotransferase), c-GT (c glutamyl transpepti-
dase), ALP (alkaline phosphatase), albumin, globulin, and
albumin/globulin ratio were measured by traditional clinical
standardized methods.
CD4+/CD8+T-cell counts
CD4+/CD8+ T-cell absolute counts were carried out by
standardized single platform counting technologies employing
cytometric methods. All reagents were obtained from BD
Biosciences (BD Biosciences, San Jose, CA) and CD4+/CD8+ T
cell counts were determined within 12 hours by using a FACS
Calibur (BD Biosciences, San Jose, CA).
HCV genotyping
A 573-bp fragment in the Core gene of HCV genome was amplified
by semi-nested PCR (first with P1-upper and P3-lower, then with P1-
upper and P2-lower). P1-upper: gcgaaaggcctt ctggta; P2-lower:
cgcacggcacgcacccggg; P3-lower: ccgcagag(a/g)tc(c/t)cccacgta. All
PCR reactions were carried out with negative controls in a designated
PCR clean room. PCR products were subject to sequence analysis by
cycle-sequencing and dye terminator methods with DNA Sequence
Analyzer ABI 3730xl (Applied Biosystems Inc., Foster City, CA).
HIV seropositive screening
HIV-1 was screened by an ELISA assay (GBI Biotech Co., Ltd.,
Beijing, China) for HIV antibody, and positive tests were confirmed
by HIV Blot 2.2 WB assay (HIV Blot 2.2 WB; Genelabs Diagnostics,
Singapore) by the local Center for Disease Control and Prevention.
Detection of HCV antibodies and viral load
All serum specimens were tested for the presence of anti-HCV
antibodies using the ARCHITECT Anti-HCV System (Abbott
Diagnostics, Abbott Park, USA). HCV antibodies were considered
reactive if the S/CO ratio (sample RLU/cutoff RLU) was greater
than or equal to 1.0. All samples with S/CO ratio between 1.0 and
5.0 were confirmed by RIBA assay (HCV BLOT 3.0, MP
diagnostics, USA). Plasma HCV viral load was determined with
the Abbott RealTime
TM HCV Amplification Kit (Abbott Molec-
ular Inc. Des Plaines, IL, USA) according to the manufacturer’s
instructions. The detection limit is 30 IU/ml, equivalent to 1.48
log10IU/ml.
Quantitative detection of HCV core antigen
Plasma HCV core antigen was quantitated using a commercial
chemiluminescent microparticle immunoassay (CMIA) (6L47
ARCHITECT HCV Ag Reagent Kit, Abbott Diagnostics, Abbott
Park, USA) according to the manufacturer’s instructions, with a
detection limit of 3 fmol/l.
Statistical analysis
Spearman’s rank-correlation, Wilcoxon matched-pairs, Mann-
Whitney U-tests and Pearson Chi-Square Tests (Yates’ correction
for continuity is used in certain situations) were performed using
GraphPad Prism 5.0 software when necessary.
Results
Characteristics of the study participants from Shangcai
prefecture, Henan, China
In this study, 354 participants were divided into 5 groups (HIV-
noninfected CHC, HIV-infected CHC, HIV-noninfected SVC,
HIV-infected SVC, and HIV infection alone) depending on the
existence of anti-HCV antibody, anti-HIV antibody, and HCV
viral load (Fig. 1A). The clinical data of participants provided by
local CDC indicated that more than 90% of the participants
infected with HCV and/or HIV were former blood donors (FBDs)
between 1990 and 1997, and sex transmission was account for
infection of the left individuals. The population of HIV-
noninfected CHC individuals, which meant HCV mono-infection
as proved by detectable viral load in plasma, accounted for the
highest proportion (129/354, 36.44%) among all five groups.
More than a quarter of the participants belonged to the population
of HIV-infected CHC (98/354, 27.68%), which was a HCV and
HIV-1 co-infected group. Both HIV-noninfected SVC (65/354,
18.36%) and HIV-infected SVC (44/354, 12.43%) populations
represented HCV seropositive individuals with undetectable HCV
viral replication (Fig. 1A), who were considered as having a prior
HCV infection and were classified as HCV non-carriers since
circulating HCV RNA was maintained at an undetectable level
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tional characteristics of HCV and HIV-1 infection (Fig. 1A), the
HCV self-recovery rates in HIV seronegative and HIV seropos-
itive populations, presented as percentage of SVC/HCV seropos-
itivity in Fig. 1B, were calculated. The results indicate that there
was no statistical difference (X
2=.237, P=0.626) in the
percentage of SVC/HCV seropositivity between HIV-1 infected
(30.99%) and noninfected (33.51%) populations. The percentage
of HCV and HIV seropositivity in all 1252 residents was
compared. The data showed that 26.84% of the participants were
HCV seropositive, while only 12.78% of the participants were
HIV seropositive. There was a significant difference in the
seropositive rate between HCV and HIV (X
2=76.9, P,0.001,
Fig. 1C). The difference between HCV and HIV infection rate
may result from a more efficient transmission of HCV than HIV
through the blood-borne route as reported previously, or from a
higher baseline prevalence of HCV than HIV.
HIV-infected SVC group had higher levels of serum ALT
and AST than HIV-noninfected SVC group while no
differences were found between CHC groups with and
without HIV infection
ALT and AST were considered as two critical enzymes for
assessing liver function. Normal clinical ranges of serum ALT and
Figure 1. The distributional characteristics of HCV- and/or HIV-infected patients involved in this study. (A) 354 HCV seropositive or HIV-
1 seropositive participants were divided into 5 different groups (HIV-noninfected CHC, HIV-infected CHC, HIV-noninfected SVC, HIV-infected SVC, HIV
infection only) depending on existence of serum HIV-1/HCV antibodies and plasma HCV RNA. The proportions of each group in 354 subjects were
indicated. (B) Comparison of the percentages of SVC subjects in HCV seropositive subjects between HIV-1 noninfected (black square) and HIV-1
infected (empty square) patients. (C) Percentage of HCV (black square) and HIV-1 (empty square) seropositive patients in whole 1252 residents. Pearson
Chi-Square tests were performed for comparing the percentage between two different groups shown in (B) and (C). Triple asterisks (***) indicate P
values below 0.001.
doi:10.1371/journal.pone.0023550.g001
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calculated the percentages of subjects with elevated ALT (.40 IU/
ml)or AST(.40 IU/ml)valuespergroup.Nosignificant difference
of either ALT (X
2=0.221, P=0.638) or AST (X
2=0.018,
P=0.895) was found between the HCV mono-infection (HIV-
noninfected CHC, 44.96% for ALT and 44.18% for AST) group
and the HCV/HIV coinfection (HIV-infected CHC, 41.84% for
ALT and 45.92% for AST) group (Fig. 2A and B). Interestingly,
there were significant differences of the percentages with values
above 40 IU/ml for ALT (X
2=3.854, P=0.05) and AST
(X
2=13.722, P,0.001) between the HIV-noninfected SVC
(10.78% for ALT and 3.08% for AST) and the HIV-infected
SVC (25.00% for ALT and 27.08% for AST). The similar
significant differences for ALT (P=0.008) and AST (P,0.001)
absolute values were found between these two subpopulations
(Fig. 2A and B). Though percentages of elevated ALT (11.11%) and
AST (22.22%) was higher in the HIV mono-infected population
than in healthy controls (0% for ALT and 5.56% for AST), there
was no statistical difference. This is possibly due to the small
population size for HIV mono-infection (n=18) and healthy
controls (n=19) (Fig. 2A and B). Additionally, no correlation was
found between ALT or AST and HCV viral load or between ALT
or AST and S/CO ratio of anti-HCV antibody in HIV-noninfected
CHC and HIV-infected CHC patients (data not shown).
S/CO ratios of anti-HCV antibodies were higher in HCV
mono-infected than HCV/HIV-1 dual infected individuals
The S/CO ratios of anti-HCV antibodies measured by the
ARCHITECT Anti-HCV System were compared among the five
groups mentioned above. Results showed that anti-HCV antibod-
ies levels were much higher in the HCV RNA positive groups than
in the HCV RNA negative group, whether with or without HIV-1
co-infection [Fig. 3A, P,0.001 for groups (a) HIV-noninfected
CHC versus (c) HIV-noninfected SVC; and groups (b) HIV-
infected CHC versus (d) HIV-infected SVC]. This result suggests
that plasma HCV RNA (positive or undetectable), influenced the
level of circulating anti-HCV antibody responses significantly. In
addition, there was a significant difference in anti-HCV antibody
levels between HCV mono-infection (HIV-noninfected CHC) and
HCV/HIV-1 co-infection (HIV-infected CHC) (P=0.025)
(Fig. 3A). Anti-HCV Abs S/CO ratios of most of HCV RNA
positive hepatitis C patients without HIV-1 infection (99.23%)
were more than or equal to 10, while a minority (9 subjects,
approximately 10%) of HCV RNA positive HCV/HIV-1 co-
infected individuals were tested to carry low S/CO ratios of anti-
HCV Abs (less than 10). This result was consistent with the fact
that HIV-1 associated immunodeficiency was closely related with
an impaired humoral immune response. Also, a significant
difference of CD4+T cell counts (P=0.025) was found between
subpopulations with anti-HCV antibody titer (S/CO) less than 10
and S/CO no less than 10 (Fig 3B). The CD4+ T cell counts of all
nine HIV-infected CHC patients with low anti-HCV antibody
titer (S/CO) were less than 500/ml (maximum value of CD4+ T
counts was 484/ml in these 9 patients). Interestingly, all these nine
patients were positive for both of HCV-RNA and core antigen.
This data suggested HIV-associated immunodeficiency had no
influence on the sensitivity of HCV core antigen detection.
Levels of plasma HCV RNA and HCV core antigen were
significantly higher in HCV/HIV-1 co-infection than in
HCV mono-infection
Plasma HCV viral load and HCV core antigen were measured
by Abbott RealTime
TM HCV Amplification Kit and Abbott
ARCHITECT HCV Ag Assay Kit. Comparisons were only
performed for HCV-RNA positive patients (HIV-noninfected
CHC and HIV-infected CHC groups) since no detectable HCV
viral load was found in SVC and HIV mono-infected patients. It
must be pointed out that HCV core antigen was undetectable in
all HCV-RNA negative patients while the majority of CHC
patients were reactive for HCV core antigen measurement (125/
129, 96.90% for HIV-noninfected CHC group and 96/98,
97.96% for HIV-1-infected CHC group). All HCV patients who
spontaneously cleared HCV infection were core antigen negative
and no patients with positive core antigen while negative HCV-
RNA was found in all 354 individuals, which solidly demon-
strated the specificity of HCV core antigen test. In addition, four
patients who were HCV RNA positive but negative for HCV
core antigen testing were found in HIV-noninfected CHC
subpopulation. HCV-RNA values of these four patients were
2.6, 2.87, 4.08 and 5.79 log10IU/ml respectively. Besides, two
patients who were HCV RNA positive but negative for HCV
core antigen testing were found in HIV-infected CHC subpop-
ulation and HCV-RNA values of these two patients were 2.90
and 3.13 log10IU/ml respectively. This data indicated that
patients who were HCV RNA positive but negative for HCV
core antigen testing were fewer and usually had very low HCV
viral loads. However, there was no evidence supporting that HIV
infection may enhance the possibility of this kind of rare event.
Statistical analysis showed that both levels of plasma HCV RNA
(P=0.0116) (Fig. 3C) and HCV core antigen (P=0.008) (Fig. 3D)
were significantly higher in HCV/HIV-1 co-infection (HIV-
infected CHC) than in HCV mono-infection (HIV-noninfected
CHC). It is conceivable that HCV replicative levels increased
faster in HIV-positive subjects than in HCV mono-infected
patients [16].
The concentrations of HCV core antigen in serum were
highly correlated with HCV RNA level in HCV mono-
infected and HCV/HIV-1 co-infected individuals
In this study, a new commercial chemiluminescent micro-
particle immunoassay kit for measurement of HCV core
antigen was used. HCV core antigen detection has a high
sensitivity as mentioned above. We found that 96.90% HIV-
noninfected CHC patients and 97.96% HIV-infected CHC
patients were reactive to the HCV core antigen measurement.
And for the first time, we reported that serum concentrations of
HCV core antigen were highly correlated with HCV RNA
levels in both HCV mono-infected (r=0.8083, P,0.001) and
HCV/HIV-1 co-infected (r=0.9524, P,0.001) patients in this
cross-sectional survey (Fig. 4A). Further analysis showed that
the correlation was highly similar in both HCV-1b and HCV-
2a genotypes CHC patients (data not shown). This suggests that
HCV core antigen measurement will be an excellent surrogate
for the HCV RNA test to monitor HCV viral replication in
clinical application though they focused on completely different
targets (protein or nucleic acid) and will provide clinical
researchers an alternative method with low cost and easy-
manipulation to evaluate the infectious status of HCV infected
patients. We further explored whether the ratio of HCV RNA
viral load/HCV core antigen concentration correlated with
infection status in HCV mono-infection and HCV/HIV-1 co-
infection. Interestingly, a significantly higher ratio of HCV
RNA viral load/HCV core antigen levels was found in HCV
mono-infected patients compared with HCV/HIV-1 co-infect-
ed patients (P=0.0414) (Fig. 4B).
HCV Core Antigen in HCV/HIV Coinfection
PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e23550Figure 2. Serum ALT and AST enzymes were comparatively analyzed among five infected groups and healthy controls. (A) ALT; (B)
AST. The percentages of patients with positive ALT or AST values (mo r et h a n4 0I U / m l )i ne a c hg r o u pw e r ei n d i c a t e di nt h em i d d l eb e s i d e
each group. Median was also shown as a horizontal bar in each group. Group a (#), b(N), c(g), d(m), e (h)a n df ( .) indicated participants of
HIV-noninfected CHC, HIV-infected CHC, HIV-noninfected SVC, HIV-infected SVC, HIV-monoinfected patients and healthy controls
respectively. Pearson Chi-Square tests (Yates’ correction for continuity was used in certain situations) were performed for comparing the
percentages with values above 40 IU/ml and Mann-Whitney U-tests were used for comparing the ALT/AST values between two different
groups. Single asterisk (*) indicate P values below 0.05. Double asterisks (**) indicate P values below 0.01 and triple asterisks (***) indicate P
values below 0.001.
doi:10.1371/journal.pone.0023550.g002
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PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e23550Figure 3. S/CO ratio of anti-HCV antibody, plasma HCV viral load and concentration of plasma HCV core antigen were analyzed
among five HCV- and/or HIV-infected groups and healthy controls. (A) S/CO ratio of anti-HCV antibody. S/CO ratio was shown as a
scatter dot plot graph. Values (S/CO) no less than 10 were considered as HCV antibody
high and percentages of patients with HCV antibody
high
were indicated for each group. (B)C D 4 + T cells counts in HIV-infected CHC subpopulations based on the level of anti-HCV antibody titer (S/
CO). (C) Plasma HCV viral load in HIV-1-noninfected CHC and HIV-infected CHC patients. (D) Concentration of plasma HCV core antigen in
HIV-noninfected CHC and HIV-infected CHC patients. Group a (#), b(N),c(g),d(m),e (h)a n df ( .) indicated participants of HIV-noninfected
CHC, HIV-infected CHC, HIV-noninfected SVC, HIV-infected SVC, HIV-monoinfected patients and healthy controls respectively. Median was
shown as a horizontal bar in each group. Mann-Whitney U-tests were performed for statistical comparison between two different groups.
Single asterisk (*) indicate P values below 0.05. Double asterisks (**) indicate P values below 0.01 and triple asterisks (***) indicate P values
below 0.001.
doi:10.1371/journal.pone.0023550.g003
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correlated with CD4+ T cell counts and S/CO ratio of anti-
HCV antibody was positively correlated with CD4+ T cell
counts in HIV-infected CHC patients with CD4+ T cell
counts less than 1000/ml
We also analyzed the correlation between HCV Abs (S/CO
value) and CD4+ T cell counts in patients with CD4 T cell counts
less than 1000/ml. Interestingly, a significant positive correlation
(r=0.3155, P=0.0033) was found in HIV-infected CHC patients
(Fig. 5A), though no statistical differences were found in the HCV
mono-infection (HIV-noninfected CHC) and HIV-noninfected
SVC groups (data not shown). As shown in Fig. 5B and C, HCV
core antigen concentration was negatively correlate (r=20.2847,
P=0.0083) with CD4+ T cell counts, while no correlation was
found between HCV viral load and CD4+ T cell counts in HIV-
coinfected CHC patients, though the concentration of serum
HCV core antigen was highly correlated with HCV RNA level in
both HCV mono-infected and HCV/HIV-1 co-infected individ-
uals as described above. These findings suggested that the
fluctuation of HCV core antigen concentration was more sensitive
than HCV viral load or HCV viral load was out of synchroni-
zation with CD4+ T cell counts in HCV/HIV-1 coinfected
individuals. In addition, the effects of HCV RNA or HCV core
Figure 4. (A) The concentration of HCV core antigen in serum were highly correlated with HCV RNA level in both HIV-noninfected
CHC (g)and HIV-infected CHC (h) patients and (B) ratio of serum HCV viral load to HCV core antigen concentration was
significantly higher in HIV-noninfected CHC (a,g) than HIV-infected CHC (b,e) patients. Spearman’s rank-correlation and Mann-Whitney
U-tests were performed in (A) and (B) separately. Single asterisk (*) indicate P values below 0.05 and triple asterisks (***) indicate P values below
0.001.
doi:10.1371/journal.pone.0023550.g004
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infected patients were analyzed and no difference was found (data
not shown).
Discussion
Since the introduction of HAART in 1996, the incidence of
most opportunistic illnesses has declined sharply [17,18], while
HCV-related liver disease has become a leading cause of
morbidity and mortality in HIV-1-infected individuals. Bica et
al. [19] and Monga et al. [20] demonstrated that end-stage liver
disease was the leading cause of death in the HIV-1 seropositive
population after HAART was introduced. In China, most of HIV-
1 infected individuals (including FBDs) have received the first-line
HAART regimes consisting of two NRTIs and one NNRTI since
2003. Preliminary data from a survey (still ongoing, unpublished)
in our laboratory indicated that HCV infections also accounted for
up to 50% of mortality in co-infected FBD individuals.
Several studies [21,22] have investigated the distribution and
correlation of HCV RNA positivity or negativity among HCV-
seropositive populations. In our present study, the percentage of
HCV RNA negative patients among anti-HCV seropositive
patients was a little higher in HIV-1 seronegative (33.51%) than
HIV-1 seropositive (30.99%) subpopulations (Fig. 1B) in enrolled
participants (more than 90% of subjects having a history of blood
donation) while this difference did not reach statistical significance.
However, it’s hard to draw a conclusion that HCV self-recovery
rate has no association with HIV-1 infection since it is difficult to
determine if HCV infection occurs before or after HIV-1
infection. If acute HCV infection and self-recovery occur before
HIV-1 infection, there should be no association between HCV
self-recovery and HIV-1 infection. Since transmission of HCV is
more efficient than HIV-1 through unsanitary blood or blood
products, it is most possible that HCV self-recovery occurred
before HIV-1 infection in the majority of FBDs with HIV-1/HCV
coinfection.
A number of cross-sectional studies have investigated the
predictors of elevated liver enzymes in HIV-infected patients
without HCV infection [23–27]. However, the effects of HIV-1
virus per se or of HAART on the progression of hepatic damage in
HCV infected patients are not well understood. Our results
indicated that HIV-associated factors may contribute to the
elevated signals (ALT and AST) of liver function since the HIV-
infected SVC group showed higher serum ALT (P=0.05) and
AST (P,0.001) than the HIV-noninfected SVC group (Fig. 2). In
our study, 80% (35/44) of HIV-infected SVC patients (including
patients with elevated ALT/AST) were taking HAART treatment,
regularly or intermittently. HAART regimes consisted of two
NRTIs (AZT/ddI or d4T/3TC), and one NNRTI (NVP). Usage
of NRTIs might slightly worsen liver function with very low
frequency and NVP might be associated with hepatitis on the
background of high baseline CD4+ T cell counts [28,29]. It is
understandable that the effect of HIV-associated factors on liver
disorders may be mild-to-moderate because no differences were
found between CHC groups with and without HIV-1 coinfection.
However, it is difficult to definitely conclude which factor played a
major role in aggravating liver damage when considering chronic
hepato-toxicity related to HAART, incomplete immune recovery,
and other possible factors from our current data.
Our data showed that the S/CO ratio of anti-HCV Abs in
HCV RNA-positive patients with or without HIV-1 co-infection
was significantly higher than that of the patients with HCV RNA
seronegativity (Fig. 3A, P,0.001), which is consistent with the
hypothesis that active HCV intrahepatic replication and stimula-
tion is crucial for the maintenance of higher levels of serum anti-
HCV responses. Theoretically, the clearance or extreme decline of
HCV intrahepatic replication would result in the gradual decrease
of HCV specific antibodies due to the loss of constant stimulation
by HCV viral components. Once the virus was cleared away, the
titer of serum HCV antibodies would drop gradually and
spontaneous seroconversion would finally occur.
Previous studies reported that HCV core Ag quantification by
ELISA method such as Lumipulse Ortho HCV Ag (Lumipulse-Ag)
(Ortho Clinical Diagnostics) with a detection limit of 50 fmol/l
can be used in the various indications of viral load monitoring,
including the evaluation of baseline viral load before therapy and
the study of early viral kinetics during therapy [30–32]. Recently, a
highly sensitive assay for HCV core antigen using a fully
automated CMIA technique has become commercially available.
The reactive cut-off for this assay was set at 3 fmol/l (S/CO=1.0)
for maximum specificity, although the limit of detection has been
calculated to be 0.83–1.24 fmol/l [33]. A number of potential
Figure 5. Correlation analysis between anti-HCV Abs response
(S/CO ratio)(A), or HCV viral load (B), or HCV core antigen
concentration (C) and CD4+ T cell counts displayed in HIV-
infected CHC patients with CD4+ T cell counts less than 1000/
ml. Spearman’s rank-correlation were performed and double asterisks
(**) indicated P values below 0.01.
doi:10.1371/journal.pone.0023550.g005
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significantly shorten the diagnostic window period for detection
of acute infection, as a tool to monitor the incidence/course of
disease in various patient groups such as hemodialysis patients and
injection drug users, as a rapid test for confirmation of active
infection in anti-HCV positive cases, and as an independent
parameter to predict response to treatment [33]. In the present
study, both of serum concentration of HCV core antigen and
HCV viral load were significantly lower in HCV mono-infection
than HCV/HIV-1 co-infection. Of note, quantitation of the
CMIA HCV core antigen assay is highly correlated with the
corresponding HCV viral load in CHC with or without HIV-1
infection (Fig 4A). Furthermore, HCV core antigen had a
detection rate comparable to using HCV RNA testing. In
contrast, serum anti-HCV titer in HCV mono-infection was
significantly higher than in co-infection. As shown in Fig. 3A, low
S/CO ratios (less than 10) of serum anti-HCV antibodies were
apparent in a minority of plasma HCV-RNA positive HCV/HIV-
1 co-infected patients (approximately 10%). However, this value is
notably higher than the percentage with low S/CO ratios (less
than 1%) in that of plasma HCV RNA positive HCV mono-
infected patients, indicating an increased risk of false negativity of
HCV infection only judged by presence of positive anti-HCV
antibody in HIV-1 coinfected patients. Fig. 3A indicated that an
undetectable anti-HCV antibody (0.09 S/CO) occurred in one
HIV-infected CHC patient (HCV viral load: 4.11 log10IU/ml;
HCV core concentration: 16.03 fmol/l; CD4+ T cells count: 346/
ml). As a result, it should be valuable to evaluate the HCV
infectious status of an HIV-1 positive population by detecting
HCV antigen or RNA. Of note, we demonstrated that a
significant positive correlation was found between S/CO ratio of
anti-HCV antibodies and peripheral CD4+ T cell counts in
HCV/HIV-1 coinfection. Importantly, HCV core antigen con-
centration was shown to negatively correlate with CD4+ T cell
counts (r=20.2847, P=0.0083), while no correlation was found
between HCV viral load and CD4+ T cell counts in HIV-
coinfected CHC patients (Fig 5B and C). These findings could be
interpreted as a hint that HCV core antigen testing was more
sensitive to reflect immune pressure than HCV RNA testing. A
possible interpretation was that the half-life of HCV core protein
was relatively shorter under the regular human immune condition
than under the immunodeficiency condition, whereas the
breakdown of serum HCV RNA was less sensitive to immune
clearance compared with HCV core protein. This interpretation
may be also partially responsible for the higher ratio of HCV RNA
to core antigen found in HIV-noninfected CHC patients
compared to HIV-infected CHC individuals (Fig 4B).
In this study, we suggested that HCV core antigen could be
used as a marker of HCV replication in anti-HCV antibody
positive, treatment-naı ¨ve population, with or without HIV-1
coinfection. It is well known that the application of HCV core
antigen testing on HCV diagnosis has several advantages. First, no
sophisticated equipments are needed for HCV core antigen testing
and the performance is time-saving in comparison with HCV
RNA testing. Second, the expected price of HCV core antigen
testing is cheaper than HCV RNA detection. Final, HCV core
antigen was shown to be much more stable in serum and plasma
than HCV RNA [34,35]. It was demonstrated that the
concentration of HCV core antigen was reproducible and stable
even after incubation at room temperature for one week, while the
concentration of HCV RNA dropped dramatically after incuba-
tion at 25uC for 24 hours [35]. Therefore, HCV core antigen
testing may act as an useful alternative marker for quantitative
analysis of HCV replication and monitoring anti-HCV therapy.
In total, our findings demonstrated that there were distinctive
serological and virological characteristics of serum HCV RNA
positive and negative hepatitis C patients with or without HIV-1
coinfection. Importantly, there was an excellent correlation
between plasma HCV viral load and the concentration of HCV
core protein not only in the HCV mono-infected population but
also in the HCV/HIV-1 coinfected population. The HCV antigen
assay detected the vast majority of HCV RNA positives with or
without HIV-1 infection (97.96% and 96.9%, respectively).
Considering HCV, core antigen testing has a comparable
sensitivity to HCV RNA qPCR. HCV core antigen concentration,
but not HCV RNA level, was negatively correlated with CD4+ T
cell counts. Our data suggested that quantitative detection of
plasma HCV core antigen may be a novel and alternative
indicator of peripheral HCV level than HCV RNA level when
evaluating the association between HCV replication and host
immune status in HCV/HIV-1 coinfected patients.
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